Literature DB >> 6339109

The effect of nifedipine on arterial pressure and reflex cardiac control.

R A McLeay, T J Stallard, R D Watson, W A Littler.   

Abstract

Nine patients with untreated essential hypertension (mean casual blood pressure 173/109 +/- 14/7 mm Hg) (+/- SD) were studied in the control state and after 16 weeks of treatment with nifedipine, 10 mg orally every 8 hours. Direct arterial blood pressure monitored continuously over 24 hours showed that nifedipine significantly reduced systolic and diastolic blood pressure throughout the day and the night. The variability of blood pressure was not altered by nifedipine therapy. There was no significant change in heart rate after nifedipine therapy. Chronic nifedipine therapy increased forearm blood flow and decreased forearm vascular resistance, consistent with its action as a vasodilator. The absolute blood pressure responses to tilt, handgrip and cold were reduced, but the percent increase in pressure was not altered by therapy. Plasma renin activity was not altered by chronic nifedipine therapy. At each study, the sensitivity and setting of the baroreflex response to i.v. phenylephrine was measured. After chronic nifedipine therapy there was resetting of the sinoaortic baroreflex and an increase in its sensitivity. Successful control of blood pressure with nifedipine led to a significant reduction in the left ventricular mass index.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6339109     DOI: 10.1161/01.cir.67.5.1084

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

1.  The cardiovascular effects of oral nifedipine and nicardipine: a double-blind comparison in healthy volunteers using transthoracic bioimpedance cardiography.

Authors:  S H Thomas; P Molyneux; J Kelly; S E Smith
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  Effect of nicardipine on haemodynamic response to stress in hypertension.

Authors:  T Takabatake; Y Yamamoto; S Nakamura; N Hashimoto; S Satoh; Y Yamada; K Kobayashi
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Acute haemodynamic effects of cromakalim in patients with angina pectoris.

Authors:  P Thomas; M S Dixon; S J Winterton; D J Sheridan
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

5.  The effect of 8 weeks treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension.

Authors:  P L Katzman; U L Hulthén; B Hökfelt
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

Review 6.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

7.  Calcium channel blockers--are they diuretics?

Authors:  M A Young; R D Watson; T J Stallard; W A Littler
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

8.  Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients.

Authors:  J R M'Buyamba-Kabangu; B Lepira; R Fagard; P Lijnen; M Ditu; K A Tshiani; A Amery
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Attenuation by diltiazem of arterial baroreflex sensitivity in man.

Authors:  J F Giudicelli; A Berdeaux; A Edouard; F Lhoste; C Richer; C Thuillez; A Jacolot
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Cardiovascular, baroreflex and humoral responses in hypertensive patients during nicardipine therapy.

Authors:  P Coruzzi; A Biggi; L Musiari; C Ravanetti; A Novarini
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.